Tag Archives: paul hastings

BIO Principles Put Patients First

Greenwood_Jim_BTN

Patient advocacy organizations play an indispensable role in the biopharmaceutical development process: They help scientists and researchers better understand what it’s like to live with the diseases they’re trying to cure. That’s why BIO and our member companies are deeply committed to meaningful partnerships with patient advocacy organizations as we work to discover new medications to help patients live longer, healthier, more fulfilling lives. Today, there are more than 250 biotechnology health care medications and Read More >

Jim's Corner  |  Leave a comment  |  Email This Post
Tags: , , , , , , , ,

How Industry Rates Interactions with the FDA

shutterstock_26191726

Kicking off day one of the BIO CEO & Investor Conference in New York City, panelists in the ‘How Industry Rates Interactions with the FDA’ session brought attendees good news – communication with the FDA has improved overall. “The improvements we have seen in increased communications between FDA and sponsors is based on a continuous dialogue that has been established over the past several years in which BIO has been at the forefront,” said Jonathan Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , , , ,

San Francisco Business Times: Two JOBS Acts are better than one

scientist, lab

Today, the San Francisco Business Times published an op-ed by OncoMed President and CEO Paul Hastings lauding the Jumpstart Our Business Startups Act (JOBS) Act for giving emerging biotech companies a much-needed boost. As Hastings points out, 80-plus companies will have gone public in the last two years with the help of the JOBS Act. As the biotech industry gathers in San Diego next month for the 2014 BIO International Convention, several CEOs in attendance will no Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , , ,

FDA Check-Up: Drug Development and Manufacturing Challenges

Paul Hastings

I have over 27 years of experience in the biotechnology and pharmaceutical industry. My current company, OncoMed Pharmaceuticals, is working at the cutting edge of oncology research, focused on antibodies that target a specific set of cells within tumors, known as tumor initiating cells, that drive the growth of the tumor and can differentiate into various cell types within the tumor. Currently, we have five products in clinical development in over 13 completed or ongoing Read More >

Public Policy  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,